Clinical Trials Browser

Myelodysplastic Syndromes, Myeloproliferative Disorders, Neutropenia, Leukemia, Myeloid, Acute

NCT07153497 2026-04-13

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

Phase 2 Not yet recruiting

132 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT07449286 2026-03-04

IFN-α in Relapse Prevention.

Phase 2 Not yet recruiting

100 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06987058 2025-09-24

ROVER-01

Phase 2 Not yet recruiting

10 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasm Metastasis, Recurrence, Leukemia, Myeloid, Acute

NCT06900088 2025-03-28

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients

Phase 2 Not yet recruiting

20 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

NCT06598969 2024-09-19

TMLI-MA

Phase 2 Not yet recruiting

58 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06602323 2024-09-19

TMLI-RI

Phase 2 Not yet recruiting

34 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

NCT06050941 2024-03-05

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS

Phase 2 Not yet recruiting

60 enrolled

MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Clinical Trials

MYELO-CAN:ABX

Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

IFN-α in Relapse Prevention.

ROVER-01

Selinexor Combined With Azacitidine Therapy in High-Risk Myeloid Neoplasms Patients

TMLI-MA

TMLI-RI

Reduced Intensive Idarubicin and Cytarabine Plus Venetoclax as First-line Treatment for Adults AML and MDS